ST. DAVID'S, Bermuda, January 28 /PRNewswire/ --

Warner Chilcott Limited (Nasdaq: WCRX) announced today a view of anticipated full year 2008 results.

Total revenues for 2008 are expected to be in the range of US$935 to US$945 million, with the growth primarily being driven by LOESTRIN 24 FE, DORYX, FEMCON FE, and TACLONEX. Gross profit margin, as a percentage of total revenues, is anticipated to be in the range of 80% to 81% in 2008.

YONKERS, New York, January 28 /PRNewswire/ --

Starting today, professionals who need to know who and what will move markets can identify expert opinion holders and track their views over time. Through Jodange's breakthrough sentiment analysis technology, custom filters allow users to understand the impact opinion holders have on products, markets and companies.

Jodange will launch its first product - Top of Mind - at the Demo '08 conference in Palm Desert, CA on January 28th.

LONDON, January 28 /PRNewswire/ -- Dean Flanders, CIO of the Novartis Research Foundation, Graham Watson, CTO at Cancer Research Technology and Martin Blueggel, COO at Protagen are among the thirty plus industry leaders presenting at the Smart Lab Exchange this February.

They join representatives from organisations such as The Hershey Company, Dow Chemical, Pfizer, L'Oreal, Cargill and Johnson & Johnson will gather to share best practice in senior level data strategy in a non-competitive cross industry forum.

TOKYO, Japan, January 28 /PRNewswire/ -- Hoya Corporation today announced its consolidated results for the Third Quarter and Nine Months ended December 31, 2007.

Third Quarter 2007 Highlights

- Net sales increased 48.6% to 147.0 billion yen compared to 98.9 billion yen for the third quarter of 2006.

- Operating income increased 1.1% to 27.5 billion yen compared to 27.2 billion yen for the third quarter of 2006.

- Ordinary income increased 12.0% to 28.1 billion yen compared to 25.1 billion yen for the third quarter of 2006.

- Net income increased 13.2 % to 22.6 billion yen compared to 19.9 billion yen for the third quarter of 2006.

- Net sales and ordinary income posted historical records on quarterly basis.

Nine Months 2007 Highlights

PALM DESERT, California and LONDON, January 28 /PRNewswire/ --

- Huddle.net Extends Power of Social Networks for Work and Play with Embedded Web Office Tools and Desktop Document Access

ABBOTT PARK, Illinois, January 28 /PRNewswire/ --

- Lopinavir/ritonavir tablet is the first and only co-formulated protease inhibitor tablet approved for use in children with HIV

Abbott (NYSE: ABT) announced today that the European Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has issued a positive opinion recommending approval of a new, lower-strength tablet formulation of the company's leading HIV protease inhibitor, Kaletra(R) (lopinavir/ritonavir). In addition, the CHMP has adopted a positive opinion, in coordination with the World Health Organization (WHO), for Aluvia(R) (lopinavir/ritonavir), the tradename of the same lower-strength tablet formulation in developing countries.